317 related articles for article (PubMed ID: 29462195)
1. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices.
Hira D; Koide H; Nakamura S; Okada T; Ishizeki K; Yamaguchi M; Koshiyama S; Oguma T; Ito K; Funayama S; Komase Y; Morita SY; Nishiguchi K; Nakano Y; Terada T
PLoS One; 2018; 13(2):e0193082. PubMed ID: 29462195
[TBL] [Abstract][Full Text] [Related]
2. First-time handling of different inhalers by chronic obstructive lung disease patients.
Harb HS; Laz NI; Rabea H; Abdelrahim MEA
Exp Lung Res; 2020 Sep; 46(7):258-269. PubMed ID: 32614625
[No Abstract] [Full Text] [Related]
3. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
4. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
[TBL] [Abstract][Full Text] [Related]
5. [A STUDY OF INSPIRATORY RESISTANCE OF DRY POWDER INHALER OF AGENTS FOR ASTHMA CONTROL].
Suda S; Konno R; Kurosawa H; Tamura G
Arerugi; 2016 Jul; 65(7):932-6. PubMed ID: 27545059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.
Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB
Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948
[TBL] [Abstract][Full Text] [Related]
8. InVitro Evaluation of Optimal Inhalation Flow Patterns for Commercial Dry Powder Inhalers and Pressurized Metered Dose Inhalers With Human Inhalation Flow Pattern Simulator.
Hira D; Okuda T; Mizutani A; Tomida N; Okamoto H
J Pharm Sci; 2018 Jun; 107(6):1731-1735. PubMed ID: 29428382
[TBL] [Abstract][Full Text] [Related]
9. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
[TBL] [Abstract][Full Text] [Related]
10. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
[TBL] [Abstract][Full Text] [Related]
11. Exhalation immediately before inhalation optimizes dry powder inhaler use.
Kondo T; Hibino M; Tanigaki T; Ohe M; Kato S
J Asthma; 2015; 52(9):935-9. PubMed ID: 26513654
[TBL] [Abstract][Full Text] [Related]
12. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dry powder inhalers with a focus on ease of use and user preference in inhaler-naïve individuals.
von Schantz S; Katajavuori N; Antikainen O; Juppo A
Int J Pharm; 2016 Jul; 509(1-2):50-58. PubMed ID: 27208655
[TBL] [Abstract][Full Text] [Related]
14. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
15. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
COPD; 2016; 13(2):167-75. PubMed ID: 26516724
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD.
van der Palen J; Moeskops-van Beurden W; Dawson CM; James WY; Preece A; Midwinter D; Barnes N; Sharma R
Int J Chron Obstruct Pulmon Dis; 2018; 13():2515-2523. PubMed ID: 30174421
[TBL] [Abstract][Full Text] [Related]
17. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.
Komase Y; Asako A; Kobayashi A; Sharma R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1365-75. PubMed ID: 25525354
[TBL] [Abstract][Full Text] [Related]
18. [The relationship between inspiratory pressure and flow through dry powder inhaler available in Japan].
Kondo T; Tanigaki T; Tazaki G; Watanabe H; Ishii H; Tsunoda T; Uruma T
Arerugi; 2010 Aug; 59(8):950-5. PubMed ID: 20820136
[TBL] [Abstract][Full Text] [Related]
19. Can patients achieve sufficient peak inspiratory flow rate (PIFR) with Turbuhaler® during acute exacerbation of asthma?
Mohd Rhazi NA; Muneswarao J; Abdul Aziz F; Ibrahim B; Kamalludin A; Soelar SA
J Asthma; 2023 Aug; 60(8):1608-1612. PubMed ID: 36650693
[TBL] [Abstract][Full Text] [Related]
20. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
